• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WANG Gongfu,LI Chen.General considerations for the pharmaceutical research of generic drugs of Perampanel Tablets[J].Journal Of Pharmaceutical Research,2025,44(11):1,087-1,090[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1960times   Download 743次 QR Code for this article
Scan with your phone!
吡仑帕奈片仿制药药学研究的一般考虑
王功富,李晨
Font:Larger+|Default|Smaller-
(国家药品监督管理局药品审评中心,北京 100076)
摘要:
吡仑帕奈片为FDA批准的首个高选择性非竞争性AMPA受体拮抗剂,治疗癫痫疗效明确且耐受性良好,近年来逐渐成为临床一线用药,其国内仿制药申报逐渐成为热点。本文通过调研相关文献,总结吡仑帕奈片国内外批准上市情况,对该品种药学研究以及多规格生物等效性豁免的主要关注点进行讨论,旨在为相关产品开发提供一定的借鉴。
关键词:  吡仑帕奈  拮抗剂  癫痫  仿制药  药学研究
DOI:10.13506/j.cnki.jpr.2025.11.008
基金项目:
Publication Date:November 25, 2025
General considerations for the pharmaceutical research of generic drugs of Perampanel Tablets
WANG Gongfu,LI Chen
(Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China)
Abstract:
Perampanel Tablets are the first highly selective noncompetitive AMPA receptor antagonist approved by the FDA, with clear efficacy and good tolerability in the treatment of epilepsy. In recent years, it has gradually become a first-line clinical drug, and its domestic generic drug application has become a hot topic. This article summarized the approved market situation at home and abroad through research  on relevant literature, and discusses the main focus of pharmaceutical research and requirement for additional strength biowaiver on this variety, aiming to provide some reference for product development.
Key words:  Perampanel  Antagonist  Epilepsy  Generic drugs  Pharmaceutical research
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.